Biotech Blueprint

Katerina Roznik
  • 5.0 (2)
  • TECHNOLOGY
  • UPDATED WEEKLY

Connecting with biotech, pharma, and academic professionals to explore the latest in science, startups, market trends, and breakthroughs. For more content, please subscribe to biotechblueprint.substack.com.

  1. 6D AGO

    Hims Launches Compounded GLP-1 Pill, CVS Forces Biosimilars – This Week in Biotech #88

    Compounded semaglutide draws FDA scrutiny as Novo Nordisk guides 2026 lower and Eli Lilly leans into a $50 Medicare copay (Jan 30-Feb 5, 2026). Follow Biotech Blueprint at biotechblueprint.com.

    6 min

  2. JAN 30

    Regenxbio FDA Hold, Sanofi Vaccine Demand Softness, and CMS Negotiation Expansion – This Week in Biotech #87

    FDA pauses two AAV programs, Sanofi reports US vaccine uptake slipping, and CMS widens negotiations to more blockbuster drugs (Jan 23-29, 2026). Subscribe to Biotech Blueprint at biotechblueprint.com.

    7 min

  3. JAN 23

    Moderna Merck V940 Shows Five Year Melanoma Durability, Biopharma Deal Activity Picks Up

    This Week in Biotech #86. Subscribe to Biotech Blueprint for free at biotechblueprint.com. KEYNOTE-942 durability, plus GSK’s $2.2B RAPT food allergy deal, BMS partners with Janux, Corcept's overall survival win, and Corvus posts Phase 1 eczema data (Jan 16-22, 2026).

    7 min

  4. JAN 9

    #CDC #Vaccine Schedule Shifts, Practice-Changing Phase 3 Wins, and Deal Heat – This Week in Biotech #84

    Subscribe to This Week in Biotech for free at biotechblueprint.com.

    7 min

  5. 12/10/2025

    Inside NImmune’s Phase 3 Push in Ulcerative Colitis

    I sat down with NImmune CEO Josep Bassaganya-Riera to talk about omilancor, their gut-restricted oral IBD drug now in Phase 3 clinical trials. We cover LANCL2 biology, their biomarker aimed at boosting response rates, and the TITAN-X platform that helps guide real development decisions. A really interesting look at how you build an oral immunology company in 2025.Follow Biotech Blueprint for free at https://www.biotechblueprint.com/NImmune Biopharma: https://nimmunebio.com/Josep's LinkedIn profile: https://www.linkedin.com/in/josep-bassaganya-riera/ Connect with me on LinkedIn: https://www.linkedin.com/in/katerina-roznik/

    33 min

  6. 12/10/2025

    FDA Tightens Vaccine Pathways, Medicare Slashes Drug Prices — This Week in Biotech #80

    Plus Duchenne’s landmark phase 3 win, a survival boost in glioblastoma, motion sickness momentum at Vanda, and ACIP’s newborn vaccine chaos (Nov 21-Dec 4, 2025). Subscribe to Biotech Blueprint for free at biotechblueprint.com.

    5 min

  7. 11/24/2025

    CDC’s Autism Reversal Shocks Experts, mRNA Flu Shot Advances, Big Oncology Wins - This Week in Biotech #79

    Subscribe to Biotech Blueprint at biotechblueprint.com

    6 min

  8. 11/14/2025

    FDA Opens New Pathway, Pfizer’s $10B GLP-1 Win, and Biotech’s Return to Offense — This Week in Biotech #78

    Subscribe to Biotech Blueprint for free at biotechblueprint.com. A week of rare regulatory momentum, strategic M&A, and meaningful clinical wins.

    8 min
See All (41)

Ratings & Reviews

5
out of 5
2 Ratings

About

Connecting with biotech, pharma, and academic professionals to explore the latest in science, startups, market trends, and breakthroughs. For more content, please subscribe to biotechblueprint.substack.com.

Information

  • Creator
    Katerina Roznik
  • Years Active
    2025 - 2026
  • Episodes
    41
  • Rating
    Clean
  • Copyright
    © Katerina Roznik
  • Show Website
    Biotech Blueprint